{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:48:14Z","timestamp":1790858894459,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1136\/ard.2007.077792","type":"journal-article","created":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T20:34:50Z","timestamp":1200083690000},"page":"1399-1405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis"],"prefix":"10.1016","volume":"67","author":[{"given":"A","family":"Konnopka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Baerwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-H","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.077792_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/41.8.899","article-title":"The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.","volume":"41","author":"Scott","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077792_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077792_bib3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/art.11170","article-title":"Five-year follow up of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.","volume":"48","author":"Verstappen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","article-title":"Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10067-006-0309-z","article-title":"Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.","volume":"26","author":"Ates","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.077792_bib8","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/ard.2004.029389","article-title":"Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.","volume":"64","author":"Nielen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077792_bib9","unstructured":"National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. 2004. Available at http:\/\/www.nice.org.uk\/niceMedia\/pdf\/TAP_Methods.pdf (accessed 3 June 2008)."},{"key":"10.1136\/ard.2007.077792_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation.","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1136\/ard.2007.077792_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00042737-200406000-00008","article-title":"A glossary of economic terms.","volume":"16","author":"Chiba","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1136\/ard.2007.077792_bib12","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/art.10471","article-title":"Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.","volume":"46","author":"Kobelt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00393-004-0570-y","article-title":"[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany.]","volume":"63","author":"Sch\u00e4dlich","year":"2004","journal-title":"Z Rheumatol"},{"key":"10.1136\/ard.2007.077792_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00393-004-0650-z","article-title":"[Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis.]","volume":"63","author":"Westhoff","year":"2004","journal-title":"Z Rheumatol"},{"key":"10.1136\/ard.2007.077792_bib15","unstructured":"Eidgen\u00f6ssisches Departement des Inneren. Analysenliste. Bern: Bundesamt f\u00fcr Bauten und Logistik BBL, 2006."},{"key":"10.1136\/ard.2007.077792_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P","article-title":"Economic consequences of the progression of rheumatoid arthritis in Sweden.","volume":"42","author":"Kobelt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/ard.2004.032789","article-title":"Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.","volume":"64","author":"Kobelt","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077792_bib18","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ).","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.077792_bib19","unstructured":"Statistisches Bundesamt. Statistisches Jahrbuch 2004. Wiesbaden: Statistisches Bundesamt, 2004."},{"key":"10.1136\/ard.2007.077792_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.10705","article-title":"Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.","volume":"48","author":"Gabriel","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ard.58.1.11","article-title":"Mortality in rheumatoid arthritis patients with disease onset in the 1980s.","volume":"58","author":"Lindqvist","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077792_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.60.3.207","article-title":"The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis.","volume":"60","author":"Zink","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077792_bib23","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/ard.2005.046367","article-title":"Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and SLE in Germany.","volume":"65","author":"Huscher","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077792_bib24","unstructured":"Statistisches Bundesamt. Fachserie 16 Heft 1. L\u00f6hne und Geh\u00e4lter, Gehalts- und Lohnstrukturerhebung 2001, Wiesbaden: Statistisches Bundesamt, 2004."},{"key":"10.1136\/ard.2007.077792_bib25","unstructured":"Statistisches Bundesamt. L\u00f6hne und Geh\u00e4lter, Arbeitskostenerhebung, Ergebnisse der Arbeitskostenerhebung 2000 f\u00fcr Deutschland. Wiesbaden: Statistisches Bundesamt, 2003."},{"key":"10.1136\/ard.2007.077792_bib26","first-page":"A62","article-title":"Deutsche Empfehlungen zur gesundheits\u00f6konomischen Evaluation - Reviedierte Fassung des Hannoveraner Konsens.","volume":"4","year":"1999","journal-title":"Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement"},{"key":"10.1136\/ard.2007.077792_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models.","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1136\/ard.2007.077792_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D","article-title":"Function and health-related quality of life: results from a randomised controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.","volume":"42","author":"Strand","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077792_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724427519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724427519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.077792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:18:42Z","timestamp":1737245922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724427519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0003496724427519"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.077792","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1103951.582960","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1103951.560851","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.077792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}